EUVIMEDUpptäck EUVIMED
CrossrefInfokort

Initial experience with high‐volume plasma exchange in patients with acute liver failure

Ji Eun Kim, Sejong Chun, Dong Hyun Sinn, Nam Joong Kim, Semi Kim, Wonseok Kang, Jong Man Kim, Gyu‐Seong Choi, Jae‐Won Joh, Duck Cho

Journal of Clinical Apheresis · 2021-06 · 36 (3) · 379-389

DOI: 10.1002/jca.21873 ↗
AbstractBibliografiska uppgifter

Abstract

Abstract Background/Aims High‐volume plasma exchange (HVPE), defined as an exchange of 8 to 12 L per day per procedure or 15% of the ideal body weight with fresh frozen plasma, has shown promising results in improving the survival of patients with acute liver failure (ALF). However, clinical evidence is limited. The aim of this study was to report our initial experience using HVPE as a bridge treatment in patients with ALF. Methods We retrospectively reviewed 32 consecutive patients awaiting liver transplantation (LT) due to ALF between 2013 and 2020 at Samsung Medical Center in Korea. HVPE has been used for patients with ALF since May 2016 at our institution. Results During the study period, 16 patients received HVPE. After HVPE, coagulopathies (INR, 4.46 [2.32‐6.02] vs 1.48 [1.33‐1.76], P < .05), total bilirubin (22.6 [9.1‐26.4] vs 8.9 [5.6‐11.3], P < .05), alanine aminotransferase (506 [341‐1963] vs 120 [88‐315], P < .05), and ammonia levels (130.6 [123.7‐143.8] vs 98.2 [84.2‐116.5], P < .05) were improved. Improvement in the hepatic encephalopathy grade was observed in four patients. Among 16 patients who received HVPE, 12 patients were bridged to LT, and three patients recovered spontaneously. The overall survival was 94% and 69%, respectively at 30 days in patients who received and did not receive HVPE ( P = .068). Among 18 patients with high chronic liver failure‐sequential organ failure assessment scores (≥13), the overall survival was significantly better for those who received HVPE than for those who did not (91% vs 29%, respectively, at 30 days, P < .05). Conclusions Our initial clinical experience with HVPE suggests that HVPE can be a viable option in improving the outcomes of patients presenting with ALF.

Kunskap som passar ditt arbete.

Från en kostnadsfri start via personlig litteratursökning till hela Research Suite.

Visa priser →

Ingår alla förlagsfulltexter?

Nej. Bibliografiska poster, abstrakt och fulltexter är olika typer av innehåll. Om en fulltext är tillgänglig beror på källan, Open Access och dina befintliga licenser. En EUVIMED-plan ersätter inga ytterligare förlagsrättigheter.

Visa priser →